Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy
Identifieur interne : 003922 ( Main/Exploration ); précédent : 003921; suivant : 003923Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy
Auteurs : A. H. Rajrut [Canada] ; R. J. Uitti [États-Unis] ; M. E. Fenton [Canada] ; D. George [Canada]Source :
- Parkinsonism and Related Disorders [ 1353-8020 ] ; 1998.
Abstract
Progressive Supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.
Url:
DOI: 10.1016/S1353-8020(97)00022-9
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000241
- to stream Istex, to step Curation: 000241
- to stream Istex, to step Checkpoint: 001480
- to stream Main, to step Merge: 003F37
- to stream Main, to step Curation: 003922
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy</title><author><name sortKey="Rajrut, A H" sort="Rajrut, A H" uniqKey="Rajrut A" first="A. H." last="Rajrut">A. H. Rajrut</name></author><author><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R. J." last="Uitti">R. J. Uitti</name></author><author><name sortKey="Fenton, M E" sort="Fenton, M E" uniqKey="Fenton M" first="M. E." last="Fenton">M. E. Fenton</name></author><author><name sortKey="George, D" sort="George, D" uniqKey="George D" first="D." last="George">D. George</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F164941C3427E1604C0E4FD5FFA1B85A367FF24F</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1016/S1353-8020(97)00022-9</idno><idno type="url">https://api-v5.istex.fr/document/F164941C3427E1604C0E4FD5FFA1B85A367FF24F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000241</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000241</idno><idno type="wicri:Area/Istex/Curation">000241</idno><idno type="wicri:Area/Istex/Checkpoint">001480</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001480</idno><idno type="wicri:doubleKey">1353-8020:1998:Rajrut A:amantadine:effectiveness:in</idno><idno type="wicri:Area/Main/Merge">003F37</idno><idno type="wicri:Area/Main/Curation">003922</idno><idno type="wicri:Area/Main/Exploration">003922</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy</title><author><name sortKey="Rajrut, A H" sort="Rajrut, A H" uniqKey="Rajrut A" first="A. H." last="Rajrut">A. H. Rajrut</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R. J." last="Uitti">R. J. Uitti</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mayo Clinic, Jacksonville, FL</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Fenton, M E" sort="Fenton, M E" uniqKey="Fenton M" first="M. E." last="Fenton">M. E. Fenton</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Saskatchewan, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author><author><name sortKey="George, D" sort="George, D" uniqKey="George D" first="D." last="George">D. George</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pathology, University of Saskatchewan, Saskatchewan</wicri:regionArea><wicri:noRegion>Saskatchewan</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Parkinsonism and Related Disorders</title><title level="j" type="abbrev">PRD</title><idno type="ISSN">1353-8020</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">3</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="211">211</biblScope><biblScope unit="page" to="214">214</biblScope></imprint><idno type="ISSN">1353-8020</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1353-8020</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progressive Supranuclear palsy (PSP) and multiple system atrophy (MSA) each respond poorly to most anti-parkinsonian drugs. We assessed PSP and MSA cases seen between 1970 and 1996 for response to amantadine (Amd) 100 mg twice daily. Of 13 MSA cases (six females, seven males), eight (61.5%) improved, four (30.8%) did not benefit and one had insufficient documentation. Adverse effects were observed in three (23.1%) cases. Of 14 PSP (three females, 11 males), six (42.9%) had some improvement, five (35.7%) had no benefit, and three (21.4%) had inadequate documentation. Adverse effects were noted in three (28.6%) cases. Improvement is likely related to NMDA antagonist properties of Amd. We recommend consideration of Amd in the management of both PSP and MSA.</div></front></TEI><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Rajrut, A H" sort="Rajrut, A H" uniqKey="Rajrut A" first="A. H." last="Rajrut">A. H. Rajrut</name></noRegion><name sortKey="Fenton, M E" sort="Fenton, M E" uniqKey="Fenton M" first="M. E." last="Fenton">M. E. Fenton</name><name sortKey="George, D" sort="George, D" uniqKey="George D" first="D." last="George">D. George</name></country><country name="États-Unis"><region name="Floride"><name sortKey="Uitti, R J" sort="Uitti, R J" uniqKey="Uitti R" first="R. J." last="Uitti">R. J. Uitti</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003922 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003922 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F164941C3427E1604C0E4FD5FFA1B85A367FF24F
|texte= Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy
}}
| This area was generated with Dilib version V0.6.29. |  |